Clinical Significance of Immunoassays for Type-5 Tartrate-resistant Acid Phosphatase
Open Access
- 1 December 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 45 (12) , 2150-2157
- https://doi.org/10.1093/clinchem/45.12.2150
Abstract
Background: Tartrate-resistant acid phosphatase (TRAP; EC 3.1.3.2) is a product of osteoclasts and a biochemical marker of bone resorption rate. However, erythrocytes and platelets contribute to total TRAP activity in serum, reducing the specificity of direct biochemical assays in serum. Osteoclast TRAP is also known as type-5 TRAP and is antigenically unique. Immunoassays are sought to improve the specificity and sensitivity of TRAP as a bone marker.Methods: We developed two colorimetric microplate assays for type-5 TRAP: an enzyme capture immunoassay to measure antibody-bound enzymatic activity, and a two-site immunoassay to measure bound enzyme protein. Both use the same monoclonal antibody (14G6) to capture type-5 TRAP, which permits determination of specific activity of serum TRAP in health and disease.Results: Both TRAP assays were linear from one-tenth to fivefold the mean value in 18 healthy subjects. In these subjects, the mean (SD) TRAP activity was 3.2 (0.54) U/L for the enzyme capture assay and 37 (13) μg/L for the two-site assay. Mean TRAP activity was not significantly increased in 64 patients with endstage renal disease requiring hemodialysis (HD) or 99 unselected patients with rheumatic diseases. By contrast, TRAP protein was increased in both the HD and rheumatic disease groups. The specific activity of TRAP in the 17 of 64 HD sera that had increased TRAP activity (0.088 U/μg) was similar to that in healthy subjects (0.091 U/μg). By contrast, the specific activity of TRAP in the 31 of 99 rheumatic sera with increased TRAP protein (0.035 U/μg) was significantly decreased.Conclusions: Wide sample distributions for TRAP activity in HD patients and TRAP protein in rheumatic disease patients suggest the presence of subpopulations of HD patients with increased TRAP activity and of rheumatic patients with increased TRAP protein. Each assay for TRAP activity and protein may have its own biological significance and clinical applications in specific groups of patients.Keywords
This publication has 23 references indexed in Scilit:
- Two‐Site Immunoassays for Osteoclastic Tartrate‐Resistant Acid Phosphatase Based on Characterization of Six Monoclonal AntibodiesJournal of Bone and Mineral Research, 1999
- Tartrate-Resistant Acid Phosphatase Forms Complexes with α2-Macroglobulin in SerumJournal of Bone and Mineral Research, 1999
- Characterization of Serum Tartrate-Resistant Acid Phosphatase and Development of a Direct Two-Site ImmunoassayJournal of Bone and Mineral Research, 1998
- Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1996
- Giant cells in arthritic synovium.Annals of the Rheumatic Diseases, 1993
- Biochemical Markers of Bone MetabolismAnnals of Medicine, 1993
- Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnoverScandinavian Journal of Clinical and Laboratory Investigation, 1991
- Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidismClinica Chimica Acta; International Journal of Clinical Chemistry, 1983
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Clinical significance of the human acid phosphatasesThe American Journal of Medicine, 1974